Pfizer Darifenacin Will Be Divested As Condition For EU Approval Of Merger
Executive Summary
Pfizer's pending urinary incontinence therapy darifenacin is the most significant asset the company needs to divest as a condition of the European approval of the Pharmacia merger
You may also be interested in...
Pfizer/Pharmacia Clears FTC: Viagra Patent Strategy, HRT Safety Are Factors
Pfizer's patent defense strategy for Viagra is one reason the Federal Trade Commission is requiring the divestiture of Phase II erectile dysfunction disorder agents as a condition of the Pfizer/Pharmacia merger
Pfizer/Pharmacia Clears FTC: Viagra Patent Strategy, HRT Safety Are Factors
Pfizer's patent defense strategy for Viagra is one reason the Federal Trade Commission is requiring the divestiture of Phase II erectile dysfunction disorder agents as a condition of the Pfizer/Pharmacia merger
Pfizer Darifenacin, Yamanouchi NDAs Filed For Urinary Incontinence
The urinary incontinence market could see the next wave of anticholinergic agents in 2003, with recent NDA submissions for two highly selective muscarinic receptor antagonists: Pfizer's darifenacin and Yamanouchi's solifenacin (YM-905)